China growth levels are the thorn in Coloplast's side, CEO reveals
![Coloplast CEO Kristian Villumsen. | Photo: Stine Bidstrup/ERH](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article14361061.ece/ALTERNATES/schema-16_9/doc7mjosgdob2duhfjv1fu.jpg)
Several markets are normalizing for Coloplast after the Covid-19 pandemic, but in China, the disease is still causing problems for the medtech firm, CEO Kristian Villumsen tells MarketWire.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Coloplast raises prices to offset energy cost spikes
For subscribers